Literature DB >> 17131145

Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia.

S L Conarello1, G Jiang, J Mu, Z Li, J Woods, E Zycband, J Ronan, F Liu, R Sinha Roy, L Zhu, M J Charron, B B Zhang.   

Abstract

AIMS/HYPOTHESIS: Under normal physiological conditions, glucagon signalling is important in glucose homeostasis. Hyperglucagonaemia or altered insulin:glucagon ratio plays a role in maintaining hyperglycaemia in subjects with type 2 diabetes. It has been reported that glucagon receptor knockout (Gcgr (-/-)) mice develop normally and have lower plasma glucose on a normal diet. The goal of the current research was to further investigate the role of glucagon signalling in metabolic control and glucose homeostasis.
METHODS: Gcgr (-/-) mice were challenged with a high-fat diet (HFD) and with streptozotocin, which induces beta cell damage. They were then analysed for whole-body and serum metabolic phenotypes as well as pancreatic islet morphology.
RESULTS: In comparison with wild-type mice, Gcgr (-/-) mice exhibited decreased body weight and food intake, reduced plasma glucose levels, and improved oral and intraperitoneal glucose tolerance. Elevated glucagon-like peptide-1 levels and reduced gastric emptying were also observed in Gcgr (-/-) mice, which also had reduced HFD-induced hyperinsulinaemia and hyperleptinaemia, and were resistant to the development of hepatic steatosis. In addition, Gcgr (-/-) mice were resistant to STZ-induced hyperglycaemia and pancreatic beta cell destruction. CONCLUSIONS/
INTERPRETATION: This study demonstrates that blocking glucagon signalling by targeted Gcgr gene deletion leads to an improvement in metabolic control in this mouse model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17131145     DOI: 10.1007/s00125-006-0481-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

1.  Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.

Authors:  P Shah; A Vella; A Basu; R Basu; W F Schwenk; R A Rizza
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Human glucagon receptor antagonists based on alkylidene hydrazides.

Authors:  Anthony Ling; Michael Plewe; Javier Gonzalez; Peter Madsen; Christian K Sams; Jesper Lau; Vlad Gregor; Doug Murphy; Kimberly Teston; Atsuo Kuki; Shenghua Shi; Larry Truesdale; Dan Kiel; John May; James Lakis; Kenna Anderes; Eugenia Iatsimirskaia; Ulla G Sidelmann; Lotte B Knudsen; Christian L Brand; Alex Polinsky
Journal:  Bioorg Med Chem Lett       Date:  2002-02-25       Impact factor: 2.823

3.  Improving the serum D-xylose test for the identification of patients with small intestinal malabsorption.

Authors:  E D Ehrenpreis; M Salvino; R M Craig
Journal:  J Clin Gastroenterol       Date:  2001-07       Impact factor: 3.062

4.  Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats.

Authors:  Yukiomi Nakade; Kiyoshi Tsukamoto; Theodore N Pappas; Toku Takahashi
Journal:  Brain Res       Date:  2006-08-01       Impact factor: 3.252

Review 5.  Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.

Authors:  Laurie L Baggio; Daniel J Drucker
Journal:  Treat Endocrinol       Date:  2002

6.  Glycemic control in mice with targeted disruption of the glucagon receptor gene.

Authors:  Janice C Parker; Kim M Andrews; Melanie R Allen; Jeffrey L Stock; John D McNeish
Journal:  Biochem Biophys Res Commun       Date:  2002-01-18       Impact factor: 3.575

7.  Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients.

Authors:  P C Butler; R A Rizza
Journal:  Diabetes       Date:  1991-01       Impact factor: 9.461

Review 8.  Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism.

Authors:  R Burcelin; E B Katz; M J Charron
Journal:  Diabetes Metab       Date:  1996-12       Impact factor: 6.041

9.  A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects.

Authors:  Sajjad A Qureshi; Mari Rios Candelore; Dan Xie; Xiaodong Yang; Laurie M Tota; Victor D-H Ding; Zhihua Li; Alka Bansal; Corin Miller; Sheila M Cohen; Guoqiang Jiang; Ed Brady; Richard Saperstein; Joseph L Duffy; James R Tata; Kevin T Chapman; David E Moller; Bei B Zhang
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

10.  Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice.

Authors:  Yin Liang; Melville C Osborne; Brett P Monia; Sanjay Bhanot; William A Gaarde; Chantal Reed; Pengxiang She; Thomas L Jetton; Keith T Demarest
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

View more
  95 in total

Review 1.  Minireview: Glucagon in stress and energy homeostasis.

Authors:  B J Jones; T Tan; S R Bloom
Journal:  Endocrinology       Date:  2012-01-31       Impact factor: 4.736

Review 2.  Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Curr Hypertens Rep       Date:  2013-10       Impact factor: 5.369

3.  Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells.

Authors:  Young Lee; Eric D Berglund; Xinxin Yu; May-Yun Wang; Matthew R Evans; Philipp E Scherer; William L Holland; Maureen J Charron; Michael G Roth; Roger H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

4.  Ectopic expression of glucagon receptor in skeletal muscles improves glucose homeostasis in a mouse model of diabetes.

Authors:  A Maharaj; L Zhu; F Huang; H Qiu; H Li; C Y Zhang; T Jin; Q Wang
Journal:  Diabetologia       Date:  2012-02-09       Impact factor: 10.122

5.  The glucagon receptor is required for the adaptive metabolic response to fasting.

Authors:  Christine Longuet; Elaine M Sinclair; Adriano Maida; Laurie L Baggio; Marlena Maziarz; Maureen J Charron; Daniel J Drucker
Journal:  Cell Metab       Date:  2008-11       Impact factor: 27.287

6.  Islets of Langerhans from prohormone convertase-2 knockout mice show α-cell hyperplasia and tumorigenesis with elevated α-cell neogenesis.

Authors:  Huw B Jones; Jaimini Reens; Simon R Brocklehurst; Catherine J Betts; Sue Bickerton; Alison L Bigley; Richard P Jenkins; Nicky M Whalley; Derrick Morgan; David M Smith
Journal:  Int J Exp Pathol       Date:  2014-02       Impact factor: 1.925

Review 7.  Dissociating fatty liver and diabetes.

Authors:  Zheng Sun; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2012-10-05       Impact factor: 12.015

Review 8.  α-cell role in β-cell generation and regeneration.

Authors:  Joel F Habener; Violeta Stanojevic
Journal:  Islets       Date:  2012 May-Jun       Impact factor: 2.694

Review 9.  Paracrine signaling in islet function and survival.

Authors:  Sean M Hartig; Aaron R Cox
Journal:  J Mol Med (Berl)       Date:  2020-02-17       Impact factor: 4.599

10.  Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.

Authors:  KyeongJin Kim; Dongryeol Ryu; Paola Dongiovanni; Lale Ozcan; Shruti Nayak; Beatrix Ueberheide; Luca Valenti; Johan Auwerx; Utpal B Pajvani
Journal:  Gastroenterology       Date:  2017-08-30       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.